首页|替格瑞洛联合血府逐瘀胶囊对ST段抬高型心肌梗死PCI术后心肌微循环及不良心血管事件的影响

替格瑞洛联合血府逐瘀胶囊对ST段抬高型心肌梗死PCI术后心肌微循环及不良心血管事件的影响

扫码查看
目的:探讨替格瑞洛联合血府逐瘀胶囊对ST段抬高型心肌梗死(STEMI)经皮冠状动脉介入(PCI)术后心肌微循环及不良心血管事件的影响.方法:选取2020年1月—2022年10月于福建省大田县总医院拟行PCI术的80例STEMI患者作为研究对象进行前瞻性研究,按照1∶1原则和随机数表法分为常规组、联合组,每组各40例.常规组采用替格瑞洛治疗,在此基础上联合组给予血府逐瘀胶囊治疗.比较两组患者一般资料、心功能[每搏输出量指数(SVI)、左室射血分数(LVEF)、左心室收缩压(LVSP)]、心肌微循环[心肌梗死区造影剂开始灌注时间(AT)、灌注达峰时间(APT)、灌注峰值强度(PI)]、炎症指标[高敏-C反应蛋白(hs-CRP)、细胞间黏附分子-1(ICAM-1)、肿瘤坏死因子-α(TNF-α)]、不良心血管事件.结果:治疗后,联合组患者LVEF、SVI、LVSP高于常规组,差异有统计学意义(t=4.007、4.716、2.887,P<0.05);治疗后,联合组患者APT、AT、PI改善幅度大于常规组,差异有统计学意义(t=3.086、3.114、2.363,P<0.05);治疗后,联合组患者hs-CRP、TNF-α、ICAM-1水平低于常规组,差异有统计学意义(t=3.633、3.092、8.277,P<0.05);治疗期间,联合组患者不良心血管事件发生率与常规组比较,差异无统计学意义(P>0.05).结论:替格瑞洛联合血府逐瘀胶囊能改善STEMI患者PCI术后微循环障碍,减轻炎症、黏附反应,促进心功能恢复.
Effects of Ticagrelor Combined with Xuefu Zhuyu Capsule on Myocardial Microcirculation and Adverse Cardiovas-cular Events After PCI for ST Segment Elevation Myocardial Infarction
Objective:To investigate the effect of Ticagrelor combined with Xuefu Zhuyu capsule on myocardial microcirculation and adverse cardiovascular events after percutaneous coronary intervention(PCI)for ST segment elevation myocardial infarction(STEMI).Methods:80 patients with STEMI who were scheduled to undergo PCI in the hospital from January 2020 to October 2022 were selected as subjects for a prospective cohort study.According to the 1∶1 principle and the random number table,they were divided into the conventional group and the combined group,with 40 cases in each group.The routine group was treated with Ticagrelor,and the combined group was treated with Xuefu Zhuyu Capsule.The general data,cardiac function[(SVI),left ventricular ejection fraction(LVEF),left ventricular systolic pressure(LVSP)],myocardial microcirculation[myocardial infarction contrast media start perfusion time(AT),perfusion peak time(APT),perfusion peak intensity(PI),inflammatory indicators[high-sensitivity C-reactive protein(hs-CRP),intercellular adhesion molecule-1(ICAM-1),tumor necrosis factor-α(TNF-α)],adverse cardiovascular events were compared.Results:The combined group had higher LVEF,SVI and LVSP after treatment compared to the conventional group(t=4.007,4.716,2.887;P<0.05).The improvement of APT,AT and PI in the combined group after treatment was greater than that in the conventional group(t=3.086,3.114,2.363;P<0.05).After combined treatment with hs-CRP and TNF-α,the level of ICAM-1 was lower than that of the conventional group(t=3.633,3.092,8.277;P<0.05).During the treatment period,there was no statistically significant difference in the incidence of adverse cardiovascular events between the combination group and the conventional group(P>0.05).Conclusion:Ticagrelor combined with Xuefu Zhuyu capsule can improve microcirculation disorder,reduce inflammation and adhesion reaction,and promote cardiac function recovery in patients with STEMI after PCI.

TicagrelorXuefu Zhuyu CapsulesMyocardial infarctionPercutaneous coronary interventionMyocardial microcirculation

张乃广、刘全炯、林爱华

展开 >

福建省大田县总医院药剂科,福建 大田 366100

福建省大田县总医院心内科,福建 大田 366100

替格瑞洛 血府逐瘀胶囊 心肌梗死 经皮冠状动脉介入 心肌微循环

2024

黑龙江医学
中华医学会黑龙江分会

黑龙江医学

影响因子:0.714
ISSN:1004-5775
年,卷(期):2024.48(18)